U.S., June 19 -- ClinicalTrials.gov registry received information related to the study (NCT07026968) titled 'A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes' on June 10.
Brief Summary: This study is a multicenter, randomized, double-blind, parallel-controlled, phase III clinical trial to evaluate efficacy and safety of the triple combination therapy of prusogliptin, dapagliflozin and metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone.
Study Start Date: June 17
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervention:
DRUG: Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose)...